国家药监局：2025年共收到创新医疗器械特别审批申请457项 近日，国家药监局发布2025年度创新医疗器械等产品注册审批情况。2025年，国家药监局按照《创新医 疗器械特别审查程序》《医疗器械优先审批程序》继续做好相关产品的审查工作，共收到创新医疗器械 特别审批申请457项，其中104项获准进入创新医疗器械特别审查程序；收到优先申请38项，其中26项获 准优先审批。 国家药监局：2025年475个中药材生产基地通过检查 央视新闻消息显示，记者从2026年全国中药注册管理和质量安全监管工作会上了解到：截至2025年年 底，全国475个中药材生产基地通过延伸检查，种植面积近124万亩，可以提供101种中药材，供给215家 中药生产企业生产275个品种。国家药监局表示，2025年监管部门聚焦中药风险预警，督促中药生产企 业主动强化监测预警，及时采取措施有效控制风险、消除隐患。完善中药说明书安全性信息，印发《已 上市中药变更药品说明书中安全性内容的申报资料撰写要求》。发布5批公告，涉及666个批准文号，完 成相关补充申请21个。 药械审批 上海医药：普瑞巴林胶囊获得菲律宾药品注册证书 2月27日，上海医药(60160 ...

Key Takeaways TEM reported 83% Q4 revenue growth, fueled by Diagnostics and Data segment strength. Tempus AI achieved positive adjusted EBITDA, though GAAP loss hit $54.2M on stock comp and charges. Illumina posted 5% revenue growth and margin gains, despite tariff-driven gross margin pressure. In 2026, MedTech players' success will hinge on their ability to balance near-term pressure with long-term transformation. Per a report by ZS, these players must address immediate operational, financial, and regulato ...

Policy Developments - Shandong Province held a meeting on February 25, 2026, to address corruption and misconduct in the healthcare sector, emphasizing the need for a coordinated effort to safeguard medical insurance funds and promote orderly development in healthcare [1] Drug and Device Approvals - Kanghong Pharmaceutical received approval from the National Medical Products Administration for clinical trials of KHN707 tablets for insomnia, a class 1 innovative drug [2] - Fosun Pharma's subsidiary received approval for clinical trials of Rumaine® (generic name: Luwomeitini tablets) for advanced non-small cell lung cancer, with global sales of MEK1/2 inhibitors projected to reach approximately $2.068 billion in 2024 [3] - China Pharmaceutical announced that its subsidiary received a drug registration certificate for injectable fosfomycin, aimed at treating acute bacterial skin and soft tissue infections [4] - Huyou Pharmaceutical received FDA approval for its new drug applications for Etoposide injection and Fluorouracil injection, enabling sales in the U.S. market [5] - Kangfang Biotech's application for the monoclonal antibody AK120 was accepted for review by the National Medical Products Administration [6] Industry Developments - Junshi Bioscience and Deqi Pharmaceuticals entered a strategic collaboration to explore the combined treatment potential of JS207 and ATG-037 for cancer patients in mainland China [8] - Illumina announced an 18-month innovation upgrade roadmap for the NovaSeq X sequencer, enhancing its capabilities and productivity [9] Capital Market Activities - Sainuo Medical announced a share repurchase plan with a total amount between 15 million and 30 million yuan, aimed at employee stock ownership plans or equity incentives [10] Financial Data - United Imaging reported a net profit of 1.888 billion yuan for 2025, a year-on-year increase of 49.60%, driven by new product launches and growth in overseas business [11] - Xiansheng Pharmaceutical projected a revenue of approximately 7.7 billion to 7.8 billion yuan for the 2025 fiscal year, with a net profit increase of 80.1% to 93.9% [12] - Sainuo Medical reported a net profit of 47.29 million yuan for 2025, a significant increase of 3,057.05% year-on-year, attributed to revenue growth and cost management [13]

BOSTON, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced financial results for the quarter and fiscal year ended December 31, 2025. Recent Highlights: Fourth quarter 2025 revenue from Continuing Operations of $23.8 million; Full Year 2025 revenue of $85.3 millionFully operationalized over $40 million in previously announced annualized cost savings supporting path to positive adjusted EBITDA and adjusted cash flow exiting 202 ...

Industry Overview - Genomics is the comprehensive study of genomes, which has intensified interest among pharmaceutical and biotechnology companies for deeper insights into disease biology and effective therapeutic strategies [1] - The global genomics market was valued at $34.23 billion in 2025 and is projected to grow from $38.24 billion in 2026 to $99.26 billion by 2034, reflecting a compound annual growth rate (CAGR) of 12.66% [8] - The global synthetic biology market was valued at $18.94 billion in 2025 and is expected to reach $69.18 billion by 2033, with a CAGR of 17.7% from 2026 to 2033 [8] Genomic Research and Applications - Insights from genomic research are increasingly used to evaluate patient responses to specific drugs, driving the development of targeted treatments and advancing personalized medicine [3] - The emergence of genome-editing technologies, particularly CRISPR/Cas9 systems, is enabling precise modifications to DNA, offering potential cures for diseases caused by genetic mutations [7] Key Companies - Illumina (ILMN) is a prominent player in genomic sequencing, recognized for its leadership in sequencing and array-based technologies [5] - Pacific Biosciences of California (PACB) focuses on advanced sequencing solutions and has seen its shares rise by 9.1% in the past year, currently holding a Zacks Rank 1 (Strong Buy) [10][12] - Caribou Biosciences (CRBU) is a clinical-stage CRISPR genome-editing biopharmaceutical company, with shares surging 34.4% in the past year and a Zacks Rank 2 (Buy) [12][14] - Sana Biotechnology (SANA) is developing cell engineering platforms for diseases like type 1 diabetes and has seen its shares increase by 37.5% over the past year, also holding a Zacks Rank 2 [15][17]

Core Viewpoint - Grail Inc's stock is experiencing a significant decline due to the failure of its three-year cancer screening trial to meet its primary goal, despite reporting better-than-expected fourth-quarter results [1]. Group 1: Stock Performance - Grail Inc's stock is down 47.7%, trading at $53.11, marking its largest single-day percentage drop on record and the lowest level since September [1]. - Year-over-year, shares are still up 11%, but they are significantly lower than the record high of $118.84 reached on January 22 [2]. - Short interest constitutes 14.5% of the stock's available float, indicating a bearish sentiment among traders [2]. Group 2: Trading Activity - The stock has seen 41 times its average daily options volume, with notable activity in the February 60 call option, which expires today [3]. - New positions are being opened in the options market, suggesting increased trading interest despite the stock's decline [3].

Insmed Inc. (NASDAQ:INSM) ranks among billionaire Stanley Druckenmiller’s 10 best stock picks. On January 23, Roth/MKM began coverage of Insmed Inc. (NASDAQ:INSM) with a Buy rating and a $212 price target. The firm pointed to Insmed’s solid position for further upside in 2026, with predictions that the company’s Brinsupri medication will continue to exceed market expectations. Illumina (ILMN) Jumps 24.8% on Earnings Beat Moreover, the firm assigned a 75% probability of success to the company’s Phase 3 EN ...

The next frontier of biology is AI-powered. Watch Illumina CEO Jacob Thaysen explain how combining AI with genomics and proteomics will transform drug discovery, along with disease diagnosis and prevention. #CES2026 #CES #AMD ...

Illumina is the world leader in DNA sequencing and a long-time AMD collaborator. Hear from Illumina CEO Jacob Thaysen as he shares how AMD adaptive computing technology turns genomic data into meaningful insights. #CES2026 #CES #AMD ...

分组1 - Hims and Hers announced a GLP-1 drug comparable to Novo Nordisk's, prompting a swift response from the FDA [2][3] - Novo Nordisk's oral semaglutide utilizes a patented technology acquired from Emisphere for drug absorption [4][5] - Hims and Hers claimed to have developed a different absorption technology using a liposomal formulation, which raises concerns about the drug's approval status [6][10] 分组2 - The FDA referred the case to the DOJ, indicating potential legal action, which is unusual for initial enforcement [6][8] - The FDA's involvement suggests serious concerns regarding the safety and efficacy of Hims and Hers' unapproved drug [10][15] - Hims and Hers has a history of aggressive market strategies, but their compliance with regulations is questioned [11][12] 分组3 - Novo Nordisk is expected to remain in the market with compounded formulations, but selling the new pill is doubtful due to regulatory challenges [13][14][15] - The competitive landscape includes other companies like Lilly, which are also exploring direct-to-consumer models [17][18] - Hims and Hers' reputation may hinder partnerships with pharmaceutical companies, impacting their market position [20]